Spectral Diagnostics, Toray Medical join forces to tackle sepsis:
This article was originally published in Clinica
Executive Summary
Canadian diagnostics developer Spectral Diagnostics and Toray Medical, a subsidiary of Japan's diversified chemicals group Toray, have formed what they claim to be the first "theranostic" alliance to improve management of severe sepsis. Under the agreement, the two companies will co-promote the use of Spectral's Endotoxin Activity Assay (EAA) for measuring levels of blood-borne endotoxin, together with Toray's Toraymyxin blood purification device for removing the noxious agent. Endotoxin is the most common mediator of sepsis and enables doctors to assess a patient's risk of developing the severe form of the condition.